Physician profile
Lei Ding
NPI 1831143726
$4,885.61
in general payments reported to CMS, 2019-2025
19 companies · $1,034 in 2025
The $1,034 reported for 2025 was more than what 88% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $644 · 2020: $145 · 2021: $448 · 2022: $551 · 2023: $1,163 · 2024: $901 · 2025: $1,034.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,098.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,097.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $827.15 | 2021-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $773.05 | 2022-2024 | Austedo Xr, Austedo, Uzedy |
| Abbvie INC. | $442.50 | 2023-2025 | Vraylar, Qulipta |
| Medtronic, INC. | $343.66 | 2024-2025 | Intellis Adaptivestim, Closurefast |
| Avanir Pharmaceuticals, INC. | $299.67 | 2019-2020 | |
| Ibsa Pharma INC. | $282.36 | 2022-2024 | Licart |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $265.20 | 2022-2023 | |
| Gilead Sciences, INC. | $250.00 | 2022-2023 | Vemlidy |
| Lilly USA, LLC | $234.19 | 2019-2025 | Kisunla |
| Axsome Therapeutics, INC. | $232.82 | 2023-2024 | Auvelity |
| Globus Medical, INC. | $165.84 | 2025 | Senza |
| Otsuka America Pharmaceutical, INC. | $142.53 | 2020-2024 | Nuedexta |
| Alkermes, INC. | $130.00 | 2025 | Lybalvi |
| Idorsia Pharmaceuticals US INC | $125.00 | 2023 | Quviviq |
| Alexion Pharmaceuticals, INC. | $116.54 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $108.77 | 2024 | Crexont |
| Janssen Pharmaceuticals, INC | $103.37 | 2019 | |
| Jazz Pharmaceuticals INC. | $22.96 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lei Ding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.